Classification Criteria for axSpA

Slides:

Advertisements

Similar presentations

REVISED JONES CRITERIA WHO Criteria for the Diagnosis of RF and RHD

Advertisements

RHEUMATOLOGY TESTING Maureen Sestito, D.O. PCOM Internal Medicine Residency.

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Anti-rheumatic Drugs In Pregnancy And Breastfeeding

Multimodal Management of Opioid-Induced Constipation

AS – the facts! Andrew Keat.

The Nurse’s Role in Inflammatory Bowel Disease

Ivabradine – A new option for Heart Failure Patients

My Treatment Approach to Rheumatoid Arthritis

Correlations of CD68, CD21, CD3, CD20 and CD117 immunohistochemical staining between paired synovial tissue (ST) and colonic mucosa (CM) biopsies of patients.

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.

Starting Strong: Initial Evaluation of the Patient With HCV

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Goals of Therapy for Patients With UC

Introduction/Background

Introducing JAK Inhibitors in Rheumatoid Arthritis

Diagnosing Rheumatoid Arthritis Early

From Conference to Practice: Big Data in Psoriasis

My Treatment Approach to Rheumatoid Arthritis

Case Challenges in Chronic Migraine

Complicated Cases in Ulcerative Colitis

Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment.

Comparing Treatment Alternatives in Ankylosing Spondylitis

Optimizing Patient Outcomes in IBD

Chronic Idiopathic Urticaria

IL-17 Inhibitors in the Management of Psoriatic Disease

Decision-making in the eRA of Treating to Target

Introduction. Family Planning and Pregnancy Management in Patients With Chronic Inflammatory Rheumatic Diseases.

Clinical Updates in RA: New Developments and Insights From Washington

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

The JAK-STAT Pathway and Graft-vs-Host Disease

Observational Studies vs. Randomized Controlled Trials (RCT)

Biotherapeutics.

Advancing the Treatment of IBD With Biologics

When Is Biologic Therapy Appropriate for HS?

Best Clinical Pearls in Hidradenitis Suppurativa:

When Is Intrathecal Drug Delivery Appropriate?

Severe Asthma and Comorbidities

Current Controversies and Advances in Hepatorenal Syndrome

Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.

What Does the Future Hold and What Will It Mean for Patients?

Essential Updates for PsA: A Complex Disease to Manage

When Is Intrathecal Drug Delivery Appropriate?

Эмийн гаж нөлөөг бүртгэн мэдээлэх, ач холбогдол

Rheumatoid Arthiritis

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Behçet Syndrome (BS) Overview

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Diagnostic Criteria Migraine Without Aura

Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.

Treatment Advances for RA

Associations between the ‘% of patients that ever used a bDMARD’ and the ‘composite score clinical criteria’, ‘composite score access to medication’ and.

Navigating the Journey

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Status of tapering in the first year of follow-up.

Biosimilars in Immune-Related Diseases

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

Associations between ‘GDP per capita (IntI$)’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with clinical outcomes.

Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Classification Criteria for axSpA

Differential Presentation of axSpA in Women vs Men

bDMARDs Approved by the European Medicines Agency (EMA) for axSpA

Pivotal RCTs for TNF Inhibitors in AS

C-axSpAnd: Phase 3 Study Evaluating Certolizumab Pegol vs Conventional Standard of Care Treatment in nr-axSpA

RAPID-axSpA: Certolizumab Pegol and Extra Spinal Manifestations

Use of TNF Inhibitors in Clinical Practice in Pregnant and Lactating Patients

Anti-TNF Treatment Prescription for WoCBA Patients With Chronic Inflammatory Diseases

Women With Chronic Rheumatic Diseases and Family Planning

Overarching Principles for Use of Antirheumatic Drugs Before and During Pregnancy

Abbreviations